Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul-Aug;69(4):556-562.
doi: 10.1016/j.ihj.2017.05.006. Epub 2017 May 27.

Cardio-Oncology - A new subspecialty with collaboration at its heart

Arjun K Ghosh  1 , J Malcolm Walker  2
Affiliations
Review

Cardio-Oncology - A new subspecialty with collaboration at its heart

Arjun K Ghosh et al. Indian Heart J. 2017 Jul-Aug.

Abstract

Cardio-Oncology is the care of cancer patients with cardiovascular disease, overt or occult, already established or acquired during treatment. Cancer patients can present with a variety of cardiovascular problems not all of which are directly related to cancer therapy (medications or radiotherapy). The cardiovascular problems of oncology patients can range from ischaemia to arrhythmias and can also include valve problems and heart failure. As such, within cardiology, teamwork is required with members of different cardiology subspecialties. The way forward will be to adopt a multidisciplinary approach to produce optimal individual care. Close collaboration between cardiology and oncology specialists in a Cardio-Oncology setting can make this happen.

Keywords: Cardio-Oncology; Cardio-Oncology Imaging; Cardio-toxicity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Multifactorial causes for QT prolongation in cancer patients. Cancer drugs can increase the QT interval via primary electrophysiological effects, or via secondary effects, such as ischaemia or heart failure.
Fig. 2
Fig. 2
Factors to be considered when deciding on intervention to prevent cardiotoxicity. GLS – global longitudinal strain, EF – ejection fraction.
Fig. 3
Fig. 3
Key considerations prior to coronary intervention in cancer patients.
See this image and copyright information in PMC

References

    1. Barac A., Murtagh G., Carver J.R. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65:2739–2746. http://www.ncbi.nlm.nih.gov/pubmed/26112199 - PMC - PubMed
    1. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:620. http://www.ncbi.nlm.nih.gov/pubmed/26292190 - PubMed
    1. Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. J Clin Oncol. 2012;30:3657–3664. - PubMed
    1. Ghosh A.K., Manisty C., Woldman S. Setting up cardio-oncology services. Br J Cardiol. 2017;24:1–5. https://bjcardio.co.uk/2017/01/setting-up-cardio-oncology-services/
    1. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016:ehw211. http://eurheartj.oxfordjournals.org/content/early/2016/08/24/eurheartj.e.... - PubMed